Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S516 methicillin-resistant coagulase-negative Staphylococcus epidermidis. MDR pathogens accounted for 58.1% of all infections. The most common resistance mechanism was extended-spectrum betalactamase, 50.8%. Fungal and viral infections were reported in 31.8% and 29.5%, respectively. Patients colonized initially with at least 1 pathogen had significantly longer fever duration (mean=4.2 days, SD=2.96) compared to non-colonized patients (mean=1.7 days, SD=2.14) (P=0.01). The median overall survival (mOS) was 52.8 months (95% CI, 19-56 months). The analysis showed no difference in mOS between colonized and non-colonized patients, and between patients with and without bacteremia (log-rank test: P=0.33, P=0.59, respectively). For patients with MDR pathogens, mOS was 32 months (95% CI, 15-56 months). In multivariate Cox regression, the significant independent predictors for shorter OS were older age (HR=1.05; 95% CI, 1.00-1.10), Epstein Barr virus reactivation (HR=1.42; 95% CI, 1.26-13.66), and pneumonia (HR=4.71; 95% CI, 1.20-18.53). Death occurred in 13.6% of patients within 100 days after allo-HSCT, 66.7% of them in the course of bacteremia. Conclusions: Assessment of colonization is an effective tool for predicting potential infection etiology, resulting in prompter targeted treatment implementation and improved outcome. Keywords: allogeneic hematopoietic stem cell transplantation, allo-HSCT, colonization, infections, overall survival CT-089 Acute Graft‑Versus‑Host Disease (GVHD) of the Heart Is an Emergency Burcu Aslan Candir MD, Samet Yaman MD, Ersin Bozan MD, Tuğçe Nur Yiğenoğlu MD, Merih Kizil Çakar MD, Mehmet Sinan Dal MD, Fevzi Altuntaş MD Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara, Turkey Context: Acute GVHD is a common complication of allogeneic hematopoietic cell transplantation (HCT) and is characterized by organ damage, inflammation, and dysfunction. Acute cardiac GVHD is a rare fatal complication. Objectives: In this abstract, we present a patient who developed acute heart GVHD after allogeneic HCT. Design: Case report. Setting: Tertiary state hospital for oncological training and research, comprehensive oncology center. Patient: A 30-year-old man was diagnosed with B-cell acute lymphoblastic leukemia. Haploidentical HCT was performed after complete remission was achieved. Thirty-three days after allogeneic HCT, the patient was admitted to the hospital with chest pain and breathing difficulties. The patient experienced acute heart failure; oliguric renal failure; bilateral pleural effusions; and nonbloody, watery diarrhea 5 times on the 34th day following haploidentical HCT. He was diagnosed with acute heart and renal GVHD. Interventions: Since his coagulation tests were abnormal and his clinical condition was not eligible for kidney or heart biopsy, the patient received a 5-day pulse of steroid therapy with 1000 mg/day of prednisolone. In addition, hemodialysis and ultrafiltration were performed, and dobutamine was administered. Outcomes: The patient’s renal function returned to normal, with an increase in urine output and no need for further hemodialysis. The patient’s heart rate and arterial tension were normal, and the pleural effusion was cleared. One month later, transthoracic echocardiography revealed that his heart function had improved, with an ejection fraction of 50% and only septal hypokinesia; the rest of his cardiac walls were normal. Conclusions: Early management is critical in patients with acute heart GVHD who are not eligible for biopsy at the time of presentation. If there is a high index of suspicion, immediate pulse steroid administration should be considered without waiting for biopsy. Keywords: graftversus-host disease, heart failure, hematopoietic cell transplantation, B-cell acute lymphoblastic leukemia, haploidentical transplant, case CT-105 Post‑Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso‑cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study November McGarvey PhD1, Abraham Lee MS1, Ken Imanak PhD1, Simran K. Tiwana PhD2, Sean Garrison PhD2, Masoom Priyadarshini MS, MPharm2 1BluePath Solutions, Los Angeles, USA. 2Bristol Myers Squibb, Princeton, USA Context: Although patients receiving CAR T-cell therapy are generally treated in the inpatient setting, opportunities for outpatient administration to reduce costs exist. HCRU and monitoring costs after CAR T-cell infusion may differ by SOC. Objective: To estimate 1-year post-infusion HCRU and cost by SOC among patients with R/R CLL treated with liso-cel in TRANSCEND (NCT03331198). Methods: Individual patient-level case report forms from TRANSCEND detailing HCRU in the 1-year time frame post-infusion were analyzed. The analysis included patients who received liso-cel at a dose level of 100×106 CAR+ T cells. HCRU categories included facility, diagnostics, procedures, and medications (excluding liso-cel acquisition costs). For total cost calculations, unit costs sourced from public databases/literature were applied to each HCRU category, adjusted to 2023 US dollars. Patients were classified as inpatients if they stayed in the hospital overnight and outpatients if they were discharged the same day, after liso-cel infusion. All outcomes were stratified by SOC and month. Results: The study population (n=108) included 94 (87%) inpatients and 14 (13%) outpatients. Mean age of inpatients and outpatients, respectively, was 64.2 and 65.1 years, and the majority were male (71.3% and 64.3%) and White (85.1% and 85.7%). Overall, 16.0% of inpatients and 7.1% of outpatients had an ICU stay. The median total hospital length of stay was 4 days longer for inpatients (18 days) versus outpatients (14 days). Most patients received antibiotics (inpatients, 98.9%; outpatients, 92.9%), tocilizumab (inpatients, 69.1%; outpatients, 57.1%), and corticosteroids (inpatients, 67.0%; outpatients, 42.9%). Estimated median 1-year total post-infusion
RkJQdWJsaXNoZXIy MTk3NTQxMg==